Merkel
First-in-Human – Treatment of Merkel Cell Carcinoma.
Phase 1 clinical study evaluating ITI-3000 in patients with Merkel cell carcinoma.
prurigo nodularis
Clinical Trial – Phase 2b/3 for prurigo nodularis treatment.
The company anticipates reporting top-line results in the second quarter of this year.
Schizophrenia
First-in-Human – Phase 3 for new Schizophrenia treatment.
Reviva anticipates expanding the clinical development of brilaroxazine into other neuropsychiatric indications.
Moderna
Clinical Trials – Moderna HIV vaccine candidate.
The vaccine was designed to prompt white blood cells turn into antibodies that could neutralize HIV.
autism spectrum disorder
Clinical Trial – Phase II autism spectrum disorder trial.
The multicentre, randomized trial of L1-79 will enroll nearly 50 subjects of the age 12 to 21 years.
Pancreatic adenocarcinoma
Clinical Trials – Pancreatic adenocarcinoma treatment.
Screening for eligible subjects for the trial has started and enrollment is anticipated to conclude in nearly one year.
liver cancer
First-in-Human – Treatment for Advanced Liver Cancer.
OUTREACH-2 study evaluating MTL-CEBPA in combination with sorafenib in up to 150 patients.
Chronic obstructive pulmonary disease
Clinical Trial – Chronic obstructive pulmonary disease.
Ensifentrine is a first-in-class product candidate that combines bronchodilator and anti-inflammatory activities in one compound.
atopic dermatitis
Clinical Trial – Phase IIb of atopic dermatitis antibody.
The trial is expected to enrol subjects across 100 sites in North America, Asia Pacific and Europe.
parkinsons
First-in-Patient – New Treatment of Parkinson’s Disease.
In preclinical studies, NE3107 was shown to improve motor symptoms as effectively as L-dopa.
